SEC Comment Letter for Kaleido Biosciences, Inc. (KLDO) (CIK 0001751299) — Mar 6, 2020
Kaleido Biosciences, Inc. (KLDO) (CIK 0001751299)
Date: March 6, 2020 · CIK: 0001751299 · Accession: 0000000000-20-002051
AI Filing Summary & Sentiment
File numbers found in text: 333-236804
Letter
March 5, 2020 Alison Lawton Chief Executive Officer Kaleido Biosciences, Inc. 65 Hayden Avenue Lexington, MA 02421 Re:Kaleido Biosciences, Inc. Registration Statement on Form S-3 Filed March 2, 2020 File No. 333-236804 Dear Ms. Lawton: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Laurie A. Burlingame, Esq.
Show Raw Text
March 5, 2020
Alison Lawton
Chief Executive Officer
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, MA 02421
Re:Kaleido Biosciences, Inc.
Registration Statement on Form S-3
Filed March 2, 2020
File No. 333-236804
Dear Ms. Lawton:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Laurie A. Burlingame, Esq.